Adverse Events During the First Administration of Rituximab According to the NCI Adult Toxicity Criteria
Patient Lymphocytes (×109/L) . | Group A . | Group B . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. 1 0.2 . | No. 2 6.5 . | No. 3 7.7 . | No. 4 11.5 . | No. 5 37.2 . | No. 6 60.8 . | No. 7 68.1 . | No. 8 71.1 . | No. 9 89.3 . | No. 10 124.0 . | No. 11 294.3 . | |
Chills | 0 | 0 | I | I | 0 | III | I | 0 | II | 0 | II |
Fever | 0 | I | II | I | 0 | I | II | 0 | II | I | 0 |
Dyspnea | 0 | 0 | 0 | 0 | 0 | I | 0 | I | 0 | 0 | III |
Tachycardia | 0 | 0 | 0 | I | 0 | I | II | 0 | II | 0 | II |
Nausea | 0 | 0 | 0 | I | 0 | 0 | II | II | III | I | III |
Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0 | II | I | I | I |
Hypokaliemia | 0 | 0 | 0 | 0 | 0 | 0 | I | 0 | I | 0 | I |
Hypocalcemia | II | 0 | I | I | 0 | 0 | II | II | II | II | I |
Increase of liver enzymes | 0 | I | 0 | 0 | 0 | II | 0 | I | III | I | I |
Elevation of LDH | I | I | I | 0 | 0 | III | I | I | III | I | I |
Hyperuricemia | 0 | I | I | 0 | I | I | I | II | 0 | II | I |
Hypoproteinemia | I | I | I | I | I | I | I | II | II | I | I |
Elevation of CRP | I | I | 0 | I | I | II | 0 | I | II | I | 0 |
Elevation of d-dimers | 0 | I | I | 0 | I | I | 0 | I | III | 0 | I |
Prolongation of prothrombin time | 0 | 0 | I | 0 | 0 | 0 | 0 | 0 | II | 0 | 0 |
Anemia | NE | 0 | 0 | I | 0 | I | I | II | I | I | I |
Thrombocytopenia | 0 | 0 | 0 | 0 | NE | I | III | I | IV | II | II |
Patient Lymphocytes (×109/L) . | Group A . | Group B . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. 1 0.2 . | No. 2 6.5 . | No. 3 7.7 . | No. 4 11.5 . | No. 5 37.2 . | No. 6 60.8 . | No. 7 68.1 . | No. 8 71.1 . | No. 9 89.3 . | No. 10 124.0 . | No. 11 294.3 . | |
Chills | 0 | 0 | I | I | 0 | III | I | 0 | II | 0 | II |
Fever | 0 | I | II | I | 0 | I | II | 0 | II | I | 0 |
Dyspnea | 0 | 0 | 0 | 0 | 0 | I | 0 | I | 0 | 0 | III |
Tachycardia | 0 | 0 | 0 | I | 0 | I | II | 0 | II | 0 | II |
Nausea | 0 | 0 | 0 | I | 0 | 0 | II | II | III | I | III |
Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0 | II | I | I | I |
Hypokaliemia | 0 | 0 | 0 | 0 | 0 | 0 | I | 0 | I | 0 | I |
Hypocalcemia | II | 0 | I | I | 0 | 0 | II | II | II | II | I |
Increase of liver enzymes | 0 | I | 0 | 0 | 0 | II | 0 | I | III | I | I |
Elevation of LDH | I | I | I | 0 | 0 | III | I | I | III | I | I |
Hyperuricemia | 0 | I | I | 0 | I | I | I | II | 0 | II | I |
Hypoproteinemia | I | I | I | I | I | I | I | II | II | I | I |
Elevation of CRP | I | I | 0 | I | I | II | 0 | I | II | I | 0 |
Elevation of d-dimers | 0 | I | I | 0 | I | I | 0 | I | III | 0 | I |
Prolongation of prothrombin time | 0 | 0 | I | 0 | 0 | 0 | 0 | 0 | II | 0 | 0 |
Anemia | NE | 0 | 0 | I | 0 | I | I | II | I | I | I |
Thrombocytopenia | 0 | 0 | 0 | 0 | NE | I | III | I | IV | II | II |
Taken into account are any abnormalities that occurred during 48 hours after onset of the first antibody infusion.
Abbreviation: NE, not evaluable due to autoimmune thrombocytopenia in patient no. 5 and autoimmune haemolysis in patient no. 1.